UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Post-COVID-19 longitudinally extensive transverse myelitis: is it a new entity?

Neurological sciences, 2022-03, Vol.43 (3), p.1569-1573

2022

Volltextzugriff (PDF)

Prevalence and incidence of multiple sclerosis in Turkey: A nationwide epidemiologic study

Multiple sclerosis, 2024-06, Vol.30 (7), p.790-799

2024

Volltextzugriff (PDF)

Retinal degeneration is associated with brain volume reduction and prognosis in radiologically isolated syndrome

Multiple sclerosis, 2020-01, Vol.26 (1), p.38-47

2020

Volltextzugriff (PDF)

Prediction of multiple sclerosis outcomes when switching to ocrelizumab

Multiple sclerosis, 2022-05, Vol.28 (6), p.958-969

2022

Volltextzugriff (PDF)

External validation of a clinical prediction model in multiple sclerosis

Multiple sclerosis, 2023-02, Vol.29 (2), p.261-269

2023

Volltextzugriff (PDF)

Evaluation of Th17-related cytokines and receptors in multiple sclerosis patients under interferon beta-1 therapy

Journal of neuroimmunology, 2013-02, Vol.255 (1), p.81-84

2013

Volltextzugriff (PDF)

The validity and reliability of the Fatigue Severity Scale in Turkish multiple sclerosis patients

International journal of rehabilitation research, 2007-03, Vol.30 (1), p.81-85

2007

Volltextzugriff (PDF)

Six-minute walk distance as a measure of functional exercise capacity in multiple sclerosis

Disability and rehabilitation, 2005, Vol.27 (22), p.1365-1371

2005

Volltextzugriff (PDF)

Factors Affecting Bone Mineral Density in Male Patients with Primary Progressive Multiple Sclerosis

Turkish journal of osteoporosis, 2020-08, Vol.26 (2), p.115-120

2020

Volltextzugriff (PDF)

Hidden Markov Model and multifractal method-based predictive quantization complexity models vis-á-vis the differential prognosis and differentiation of Multiple Sclerosis’ subgroups

Knowledge-based systems, 2022-06, Vol.246, p.108694, Article 108694

2022

Volltextzugriff (PDF)

Investigating the Side Effects of Treatments Among Different Age and Gender Groups of Multiple Sclerosis Patients (P2-6.015)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

Real World Ocrelizumab Experience of a Tertiary Center in Turkey (4528)

Neurology, 2021-04, Vol.96 (15_supplement)

2021

Volltextzugriff (PDF)

The Role of C3 and C4 Complement Levels in the Differential Diagnosis of Central Nervous System Demyelinating Diseases (P14-3.016)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

Combined Central and Peripheral Demyelination in a Case With Sjogren Syndrome

The Neurologist (Baltimore, Md.), 2022-11, Vol.27 (6), p.354-356

2022

Volltextzugriff (PDF)

The acute effect of cervical mobilization on balance in patients with multiple sclerosis: a single-blind, randomized, controlled trial

Neurological research (New York), 2024-01, Vol.46 (1), p.65-71

2024

Volltextzugriff (PDF)

A clinically isolated syndrome: A challenging entity

Journal of neurology, 2008-11, Vol.255 (11), p.1625-1635

2008

Volltextzugriff (PDF)

Faible activité de la maladie après un traitement de 4 ans par ocrelizumab (OCR) chez des patients naïfs de traitement atteints de sclérose en plaques récurrente-rémittente (SEP-RR) à un stade précoce ; données de l’étude de phase IIIb ensemble

Revue neurologique, 2024-04, Vol.180, p.S146-S147

2024

Volltextzugriff (PDF)

Low Disease Activity Over 4 Years of Ocrelizumab Therapy in Treatment-naive Patients with High-activity, Early-stage Relapsing-remitting Multiple Sclerosis in the ENSEMBLE Study (P10-6.007)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

Faible activité de la maladie chez des patients naïfs de traitement, atteints de sclérose en plaques récurrente-rémittente (SEP-RR) précoce, ayant reçu ocrélizumab (OCR) pendant 2 ans dans l’étude de phase IIIb ENSEMBLE

Revue neurologique, 2023-04, Vol.179, p.S168-S168

2023

Volltextzugriff (PDF)

Navigating the discontinuation of multiple sclerosis first line treatments: A paradigm shift in patient care

Multiple sclerosis and related disorders, 2024-04, Vol.84, p.105503-105503, Article 105503

2024

Volltextzugriff (PDF)

Infusion-Related Reactions With Ocrelizumab: Risk Factors, Symptom Management and Patient Choices in the ENSEMBLE PLUS Study (P7-3.003)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

Low Disease Activity Over 4 Years of Ocrelizumab Therapy in Treatment-Naive Patients With Early-Stage Relapsing-Remitting Multiple Sclerosis; the Phase IIIb ENSEMBLE Study (S46.004)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

1 – 25 von 103

Suche als RSS-Feed

Aktive Filter

KollektionFree E-Journal (出版社公開部分のみ）

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(78)
Mit Volltextzugriff
(65)

Publikationsform

Artikel
(102)
Tagungsberichte
(1)

Sprache

Englisch
(101)
Französisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(68)
Life Sciences & Biomedicine
(66)
Neurosciences & Neurology
(55)
Humans
(54)
Clinical Neurology
(50)
Multiple Sclerosis
(47)
Female
(43)
Adult
(40)
Male
(36)
Neurosciences
(24)
Middle Aged
(22)
Magnetic Resonance Imaging
(18)
Neurology
(17)
Young Adult
(14)
Disease Progression
(12)
Patients
(12)
Multiple Sclerosis, Relapsing-Remitting - Drug Therapy
(11)
Disability Evaluation
(10)
Multiple Sclerosis - Drug Therapy
(10)
Medicine
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Post-COVID-19 longitudinally extensive transverse myelitis: is it a new entity?

Prevalence and incidence of multiple sclerosis in Turkey: A nationwide epidemiologic study

Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosis

Retinal degeneration is associated with brain volume reduction and prognosis in radiologically isolated syndrome

Prediction of multiple sclerosis outcomes when switching to ocrelizumab

External validation of a clinical prediction model in multiple sclerosis

Impact of COVID-19 vaccination or infection on disease activity in a radiologically isolated syndrome cohort: The VaxiRIS study

Evaluation of Th17-related cytokines and receptors in multiple sclerosis patients under interferon beta-1 therapy

The validity and reliability of the Fatigue Severity Scale in Turkish multiple sclerosis patients

Six-minute walk distance as a measure of functional exercise capacity in multiple sclerosis

Factors Affecting Bone Mineral Density in Male Patients with Primary Progressive Multiple Sclerosis

Hidden Markov Model and multifractal method-based predictive quantization complexity models vis-á-vis the differential prognosis and differentiation of Multiple Sclerosis’ subgroups

Investigating the Side Effects of Treatments Among Different Age and Gender Groups of Multiple Sclerosis Patients (P2-6.015)

Real World Ocrelizumab Experience of a Tertiary Center in Turkey (4528)

The Role of C3 and C4 Complement Levels in the Differential Diagnosis of Central Nervous System Demyelinating Diseases (P14-3.016)

Combined Central and Peripheral Demyelination in a Case With Sjogren Syndrome

The acute effect of cervical mobilization on balance in patients with multiple sclerosis: a single-blind, randomized, controlled trial

A clinically isolated syndrome: A challenging entity

Faible activité de la maladie après un traitement de 4 ans par ocrelizumab (OCR) chez des patients naïfs de traitement atteints de sclérose en plaques récurrente-rémittente (SEP-RR) à un stade précoce ; données de l’étude de phase IIIb ensemble

Low Disease Activity Over 4 Years of Ocrelizumab Therapy in Treatment-naive Patients with High-activity, Early-stage Relapsing-remitting Multiple Sclerosis in the ENSEMBLE Study (P10-6.007)

Faible activité de la maladie chez des patients naïfs de traitement, atteints de sclérose en plaques récurrente-rémittente (SEP-RR) précoce, ayant reçu ocrélizumab (OCR) pendant 2 ans dans l’étude de phase IIIb ENSEMBLE

Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study

Navigating the discontinuation of multiple sclerosis first line treatments: A paradigm shift in patient care

Infusion-Related Reactions With Ocrelizumab: Risk Factors, Symptom Management and Patient Choices in the ENSEMBLE PLUS Study (P7-3.003)

Low Disease Activity Over 4 Years of Ocrelizumab Therapy in Treatment-Naive Patients With Early-Stage Relapsing-Remitting Multiple Sclerosis; the Phase IIIb ENSEMBLE Study (S46.004)

Aktive Filter

Suchergebnisse filtern